Ads
related to: fda, prostate cancer
Search results
Opko Health (OPK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 5 days agoFDA concluded that the 4Kscore Test had the appropriate sensitivity of 96.9% and negative predictive value of 95.9% to contribute to an overall...
Earnings call: FibroGen reports Q1 2024 results, optimistic about pipeline By Investing.com
Investing.com· 5 days agoPositive Phase 1 results for FG-3246 in metastatic castration-resistant prostate cancer were also...
Abbott’s Jennifer Jones-McMeans on treating PAD below the knee
MedTech Dive via Yahoo Finance· 3 days agoJennifer Jones-McMeans, a leader in Abbott’s vascular unit, discussed the company’s newly approved...
Q1 2024 OPKO Health Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 4 days ago...I would like to remind you, focus coal was approved by the FDA, supported by its analytical and clinical data FDA concluded that the focus charge was had the appropriate sensitivity at 96.9% and negative predictive value of 95.9% contributed to an overall beneficial clinical decision as to...
Do Patients Benefit from Cancer Trial Participation?
Medscape· 5 days agoA recent meta-analysis found that overall investigational drugs demonstrate modest survival benefits and greater toxicities for patients participating in cancer clinical trials.
FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoFibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript May 6, 2024 FibroGen, Inc. misses on...
Phillip Febbo on Recommendations for Equitable Implementation of Liquid Biopsy
MedPage Today· 4 days agoLiquid biopsies -- tests that detect circulating tumor DNA (ctDNA) in the bloodstream -- have the...
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue...
Digital Journal· 3 days agoTORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoOPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript May 7, 2024 OPKO Health, Inc. misses...
Q1 2024 FibroGen Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoThis program also includes the development of an associated CD46 targeted PET...FG-3246, we have recently submitted an IND for FG-3165, our Galectin-9 monoclonal antibody and await ...
